We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable 5-MeO-DMT product candidate which is delivered via […]

We are a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. We are pioneering a precision gene editing approach to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in […]

We are a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. Our vision is to elevate precision medicine to the forefront of every cancer treatment journey, as we believe that each patient living with cancer deserves the opportunity to benefit from a genomically-driven treatment […]

We are a leading provider of critical reagents that enable the discovery, development and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Our 3,000 active customers span the continuum of the life sciences market, including leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and […]

We are a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. We have developed a proprietary protein degradation platform, called QuEEN, that enables us to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to […]

We are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile—requiring rigorous patient […]

(Note: Soulgate Inc. withdrew its IPO prospectus in an SEC filing dated June 9, 2022. Last year: Soulgate postponed its IPO on Wednesday morning, June 23, 2021 – hours ahead of its scheduled pricing that night. Soulgate filed its F-1 on May 10, 2021.) (Note: This is an IPO of 13.2 million American Depositary Shares (ADS), […]

Our mission: Eliminate the organ transplant waiting list. We are a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Organ disease is a major public health issue. According to the American Transplant Foundation there are an estimated 114,000 people in the United States […]

Note: This is the sixth SPAC or blank-check company created under the JAWS name and led by Barry Sternlicht, the founder, chairman and CEO of Starwood Capital. (Incorporated in the Cayman Islands) We intend to focus our efforts on wireless communications and related technology/product/service businesses that have attractive growth-oriented characteristics and strong underlying demand drivers. We […]

Note: This is the second blank-check company — in a group of three under the Corner Growth Acquisition name – established by John Cadeddu and Marvin Tien, the co-founders and general partners of Corner Ventures, a venture capital firm focused on investing in fast-growing technology companies. (Incorporated in the Cayman Islands) Our focus will be […]